Stevenage Bioscience Catalyst

ABOUT

The site is located close to Junction 7 of the A1 (M) between the motorway and the Stevenage to London rail line.

Offer:

With a unique focus on open innovation, Stevenage Bioscience Catalyst was created to bring academia, biotech and pharma companies together to drive advances in healthcare research moreeffectively. This vision was embraced and jointly funded (£38Mn) by BIS, GSK, Wellcome Trust and Innovate UK (formerly TSB).

The Bioscience Catalyst opened in 2012 and is co-located with GlaxoSmithKline’s UK R&D facility and provides both Incubator and Accelerator spaces, totalling c.5,500 sq m of laboratory, office and networking space. In late 2014 the Cell Therapy Catapult announced it had chosen to deliver a cutting edge Cell Therapy Manufacturing Centre within the Bioscience Catalyst campus. This £55mn investment will provide a facility for Bioscience businesses to manufacture late stage trial and commercial advanced therapeutic medicinal products.

This new ‘incubator plus’ model, characterized by co-location with large Pharma and access to an unrivalled range of expertise and technical services, is focused on high-quality, IP-based tenants.

Businesses on the site:

www.stevenagecatalyst.com/tenants

Sectors represented:

• Therapeutics
• Diagnostics/Devices
• Manufacturing/Technology
• Big data/analytics
• Support/consultancy

Life Science workspace type:

Main workspace types include:

• The Incubator Building – Ideally suited to start-up biotech companies, this 4,750 sq m building is split between office space(40 per cent) and laboratories (60 per cent). Includes hot desks andvirtual office facilities.
• The Accelerator Building Providing four, 100 sq m of working space for up to 150 people, the building is split between laboratories (60 per cent) and office space (40 per cent).
• Community Lab – flexible workspace for new ventures, on-site tenants as well as off-site companies to access. It has a range of basic equipment that can be accessed within the Community zone as well as more sophisticated equipment that can be rented by the hour.
• Cell Therapy Manufacturing Centre – facilities for businesses seeking to manufacture products at the later trial stages and for commercialisation. Space will be flexible with users renting appropriate space and facilities on licence to meet their needs.

Growth Capacity:

With long-term plans to expand the campus by five fold from the first phase to the third phase, Phase 2 of the SBC will provide space for current tenants as they grow as well as space for new tenants.

It is expected the 25 acre Campus will ultimately accommodate 1,500 employees.

Other amenities:

• The HUB – Conference and Meetings facilities
• Access to GSK lecture theatre
• Shared technical facilities
• Communal area with access to chemistry services and equipment
• Access to electronic journals
• Fitness suite
• Access to GSK Restaurant /Café/Nucleus
• Free shuttle bus from station to site

Institutional presence:

The University of Cambridge has located a number of translational drug discovery projects to its SBC laboratories

The University College London has located translational research projects and spin-outs

MRC Technology, a technology transfer organisation

The BIA, Johnson & Johnson Innovation Centre and Lilly have partnering desks at SBC.

www.stevenagecatalyst.com